NeuroBo Pharmaceuticals, Inc. Made Big Gain
NeuroBo Pharmaceuticals, Inc. (NRBO:NASDAQ) soared at $20.79, a gain of 42.4%. The stock got featured on our News Catalysts scanner on Thu, Sep 15, 2022 at 09:14 AM in the 'PATNERSHIP' category. From Tue, Sep 06, 2022, the stock recorded 50.00% Up Days and 45.45% Green Days
The stock spiked on Tue, Sep 13, 2022 at $63.85 with a volume of 9M+.
About NeuroBo Pharmaceuticals, Inc. (NRBO:NASDAQ)
NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Its product candidate comprises NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy; NB-02, which treat the symptoms of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid-beta plaque deposition; Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia.
Top 10 Gainers:
- Amprius Technologies Inc. (AMPX:NYSE), 86.44%
- Powerbridge Technologies Co., Ltd. (PBTS:NASDAQ), 60.62%
- NeuroBo Pharmaceuticals, Inc. (NRBO:NASDAQ), 42.4%
- Virax Biolabs Group Limited (VRAX:NASDAQ), 41.3%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 28.42%
- Trxade Group, Inc. (MEDS:NASDAQ), 27.7%
- Mobile Global Esports Inc. (MGAM:NASDAQ), 26.45%
- SaverOne 2014 Ltd. (SVRE:NASDAQ), 22.4%
- Yunji Inc. (YJ:NASDAQ), 20.19%
- Fennec Pharmaceuticals Inc. (FENC:NASDAQ), 15.78%